Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
PRME Stock Chart & Stats
$4.66
-$0.14(-4.27%)
At close: 4:00 PM EST
$4.66
-$0.14(-4.27%)
Day’s Range― - ―
52-Week Range$1.11 - $6.94
Previous CloseN/A
Volume144.88K
Average Volume (3M)2.72M
Market Cap
$841.18M
Enterprise Value$887.92M
Total Cash (Recent Filing)$208.43M
Total Debt (Recent Filing)$118.14M
Price to Earnings (P/E)―
Beta3.06
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding180,510,650
10 Day Avg. Volume2,990,601
30 Day Avg. Volume2,720,926
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.26
Price to Sales (P/S)116.10
P/FCF Ratio-2.66
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue148.56
Enterprise Value/Gross Profit-22.27
Enterprise Value/Ebitda-4.59
Forecast
1Y Price Target
$5.50Price Target Upside18.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$17.20M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentProgress toward initiating clinical trials for the company's preclinical gene editing programs could restore investor confidence and unlock value tied to curative therapies.
Platform BreadthA mutation-agnostic prime editing approach could enable treatment of a broader patient population across multiple high-value indications, supporting a larger commercial opportunity if clinical milestones are met.
PM577 Efficacy And SafetyStrong preclinical results for PM577 demonstrating durable liver correction and restoration of copper balance suggest potential for a safer, disease-modifying treatment for Wilson's disease.
Bears Say
Investor SentimentSubstantial short interest in the stock signals investor skepticism and can intensify downward pressure on the share price when negative news emerges.
Payer And Pricing PressureVery high costs associated with existing treatments for the target disease may draw payer scrutiny and create hurdles for achieving favorable reimbursement and broad market uptake for new therapies.
Sector VolatilityHigh-profile deals and clinical setbacks across the gene editing sector have increased market volatility, which can amplify share price swings for companies developing similar technologies.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $841.18M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is May 07, 2026 which is in 64 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Currently, no data Available
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 180,510,650 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (18.03% Upside)
$5.50 (18.03% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 6.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
90.90%
12-Months-Change
Fundamentals
Return on Equity
-112.34%
Trailing 12-Months
Asset Growth
15.69%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$5.50
▲(18.03% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
Currently, No data available
---